EntryPoint Capital’s Puma Biotechnology PBYI Stock Holding History
Bought
Maintained
Sold
Other funds holding PBYI
ACA
EntryPoint Capital's PBYI Position: Q2 2026 in Review
EntryPoint Capital reduced its Puma Biotechnology (PBYI) stake by 30% in Q2 2026, selling an estimated $118K and leaving 37,386 shares worth $303K. The position accounts for 0.07% of the portfolio, ranked #550.
EntryPoint Capital first reported a position in PBYI in Q1 2024 and has held it in 4 quarters since. The position peaked at $342K in Q1 2026. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.
- EntryPoint Capital held 37,386 shares of Puma Biotechnology worth $303K as of Q2 2026.
- EntryPoint Capital sold 16,078 Puma Biotechnology shares in Q2 2026, an estimated $118K.
- Puma Biotechnology made up 0.07% of EntryPoint Capital's portfolio in Q2 2026, its #550 holding.
- EntryPoint Capital first reported a position in Puma Biotechnology in Q1 2024 and has held it in 4 quarters since.
- EntryPoint Capital's Puma Biotechnology position peaked at $342K in Q1 2026.
- 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.